Abstract
Pempidine, and other highly active ganglion blocking agents of the polyalkylpiperidine series, were developed from tertiary alkylamines, themselves weakly active, on the hypothesis that high activity was conferred by the presence in the molecule of a sterically hindered secondary or tertiary nitrogen atom. Pempidine and its N-ethyl homologue (26539) resembled mecamylamine qualitatively. All three drugs blocked sympathetic and parasympathetic ganglia; this action was slow in onset and protracted. They blocked neuromuscular transmission, but only about one hundredth as powerfully as ganglionic transmission. They caused a fall in amplitude and rate of the isolated heart, and reduced coronary flow. They had local anaesthetic properties in one of four tests used. They caused tremor. All were well absorbed when administered orally. Pempidine was about twice as active as mecamylamine on ganglia, but only about one half to one quarter as toxic as judged by death, growth, induction of tremor, or cardiotoxicity. Compound 26539 was also quantitatively superior to mecamylamine in respect of these safety margins, but unlike pempidine or mecamylamine damaged the pituitary gland and testis when administered daily for several months. The mode of action of the three drugs is discussed: the results give tentative support for the hypothesis that their action is intracellular.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BENNETT G., TYLER C., ZAIMIS E. Mecamylamine and its mode of action. Lancet. 1957 Aug 3;273(6988):218–222. doi: 10.1016/s0140-6736(57)91598-2. [DOI] [PubMed] [Google Scholar]
- BOGUE J. Y., CARRINGTON H. C. The evaluation of "mysoline," a new anticonvulsant drug. Br J Pharmacol Chemother. 1953 Jun;8(2):230–236. doi: 10.1111/j.1476-5381.1953.tb00784.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- CHEN G., PORTMAN R., WICKEL A. Evaluation of ganglionic blocking agents by blood pressure and by tension of the urinary bladder in dogs against 1,1-dimethyl-4-phenylpiperazinium iodide (DMPP). Arch Int Pharmacodyn Ther. 1954 Jan;96(3-4):291–303. [PubMed] [Google Scholar]
- CORCORAN A. C., DUSTAN H. P., PAGE I. H., SCHNECKLOTH R. E. Mecamylamine in treatment of hypertensive disease; observations on an unusual neuromuscular complication. J Am Med Assoc. 1956 Oct 27;162(9):868–875. doi: 10.1001/jama.1956.02970260018006. [DOI] [PubMed] [Google Scholar]
- GRANT A. P., BOYD J. S. Mecamylamine ileus as a surgical emergency. Lancet. 1957 Apr 6;272(6971):713–715. doi: 10.1016/s0140-6736(57)91170-4. [DOI] [PubMed] [Google Scholar]
- HARINGTON M., KINCAID-SMITH P. Psychosis and tremor due to mecamylamine. Lancet. 1958 Mar 8;1(7019):499–501. doi: 10.1016/s0140-6736(58)90810-9. [DOI] [PubMed] [Google Scholar]
- LEE G. E., WRAGG W. R., CORNE S. J., EDGE N. D., READING H. W. 1:2:2:6:6-Pentamethylpiperidine: a new hypotensive drug. Nature. 1958 Jun 21;181(4625):1717–1719. doi: 10.1038/1811717a0. [DOI] [PubMed] [Google Scholar]
- MILNE M. D., ROWE G. G., SOMERS K., MUEHRCKE R. C., CRAWFORD M. A. Observations on the pharmacology of mecamylamine. Clin Sci. 1957 Nov;16(4):599–614. [PubMed] [Google Scholar]
- PATON W. D. M., ZAIMIS E. The methonium. Pharmacol Rev. 1952 Sep;4(3):219–253. [PubMed] [Google Scholar]
- PAYNE J. P., ROWE G. G. The effects of mecamylamine in the cat as modified by the administration of carbon dioxide. Br J Pharmacol Chemother. 1957 Dec;12(4):457–460. doi: 10.1111/j.1476-5381.1957.tb00165.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- PERRY H. M., Jr, SCHROEDER H. A. Neurological manifestations after antihypertensive therapy with mecamylamine. J Am Med Assoc. 1957 Jul 27;164(13):1455–1458. doi: 10.1001/jama.1957.02980130031007. [DOI] [PubMed] [Google Scholar]
- STONE C. A., TORCHIANA M. L., NAVARRO A., BEYER K. H. Ganglionic blocking properties of 3-methylaminoisocamphane hydrochloride (mecamylamine): a secondary amine. J Pharmacol Exp Ther. 1956 Jun;117(2):169–183. [PubMed] [Google Scholar]